



*"Investing wisely in
healthcare innovation
for the benefit of society
and our members"*



April 2016

Members: 156

Countries: 13

Investments: 2

MedPro Launches Third Investment

Conference call scheduled for next Tuesday, April 26

We are excited to bring you the opportunity to invest in Impleo Medical, a compelling privately-held company with an optimal solution for treating GERD (Gastroesophageal Reflux Disease), a condition afflicting over 25% of the American adult population on a weekly basis. Chronic GERD leads to esophagitis, Barrett's Esophagus, Indigestion and Esophageal Cancer.

As you may be aware, people with GERD often take Nexium or other Proton Pump Inhibitors (PPIs). These seldom remediate the problem, though. Additionally, the USFDA recently published a warning that long term use of PPIs poses a serious risk of chronic kidney disease as well as a number of infectious diseases. With the exception of Impleo's bulking agent, other recognized methods of coping with GERD are all in-patient surgical procedures requiring hospitalization, high cost and a risk of inflammation.

Impleo's approach is differentiated. The company uses a proprietary bulking agent which gastroenterologists can insert in the mucosa at the base of the esophagus in a minimally

invasive outpatient endoscopic procedure at far lower cost and risk. The bulking agent has been approved by the FDA and used effectively to remediate incontinence for 15 years. In early clinical trials in GERD, the Impleo bulking agent demonstrated effectiveness in all nine of the patients over a 12 month period with no side effects. A different bulking agent supported by another company was unable to secure FDA approval for incontinence and could be expected to fail in remediating GERD if an effort was made to bring it to an FDA trial in GERD.

Impleo's desirable method (the bulking agent is treated as a medical device), appealing valuation (\$5.5 million) and likelihood of securing insurance reimbursement (a reimbursement code already exists) for both the bulking agent and the gastroenterologist, along with our specialist's positive review and a reasonable exit strategy make the investment opportunity attractive.

A conference call is scheduled for Tuesday, April 26th at 12:30 pm EST. It is open to all who wish to learn more. On the line will be Impleo's CEO as well as its clinical advisor. Call-in numbers are as follows (no PIN needed):

U.S., Canada, Europe: 646-665-7615

Australia: (02) 8417 2302

Israel: 072-223-7397

For other countries: <https://www.uberconference.com/international>

B-Temia in the News

Making an impact

Just recently, MedPro closed on its second investment: B-Temia. Recall that the Quebec-based medical device company entered the market with their Keeogo™ product, which gives people with disabilities the ability to regain autonomy in walking, climbing stairs, and performing everyday necessary and recreational activities. A recent press release validates all of this and more.

"One month after enabling a young female stroke survivor from Hamilton, ON, to climb the Grand Canyon, B-TEMIA, Inc. strikes again by providing an opportunity for an Asheville, NC, woman with an incomplete spinal cord injury to walk her first steps following paralysis, thanks to Keeogo™, a unique robotized walking device based on B-TEMIA's proprietary

Dermoskeleton™ technology."

To read the entire account: <http://www.b-temia.com/walking-climbing-grand-canyon-thanks-biorobotic-technology-developed-b-temia/>

On the Horizon

More deals under consideration

There are a handful of investment opportunities currently being evaluated. Here is a glance at some of the target indications and therapeutic approaches across these companies:

Immuno-Oncology

In a unique and opportunistic play, MedPro has successfully licensed technology from scientists at a major medical research institution into a NewCo, where HER2 positive prostate, breast and other cancers are the targets. Early clinical results have shown strong patient responses to the vaccine. The institutional source of the technology will continue to support the NewCo in future trials and complement external funding, which is forthcoming. MedPro placed a CEO with expert knowledge to team with the scientists and who has been actively pushing progress.

A Protective Device for Cell Delivery

A publicly traded company that remains on our radar has developed an implantable cell pouch which houses and protects therapeutic cells. The primary target is the treatment of diabetes. There has been clinical proof of concept demonstrated in patients who have received allogenic islet cells harvested from cadavers. The pouch has become well vascularized, enabling the islets to produce insulin in response to changes in blood glucose levels. The Company also plans to use the pouch to house stem cells and other cells which have been epigenetically engineered to produce insulin.

Neurological Diseases

Another publicly traded company that has been reviewed favorably by one of our specialists at first pass (information gathering is ongoing) focuses on treating the ever-difficult Alzheimer's disease, Fragile X Syndrome (FXS) and Niemann Pick Type-C (NPC) through the use of a

protein kinase C (PKC) activator.

Scleroderma

A private company seeking to treat late stage diffuse systemic scleroderma (dcSSc) has developed a personalized biologic that is ready to enter a pivotal clinical trial upon completion of a capital raise. The company has a genotype marker that predicts which patients will respond to its treatment and which could have adverse reactions. A specialist's review is pending.

Others

It should be noted that the above opportunities only represent a subset of potential future investments. Our interests and capacity to evaluate opportunities in many fields of medical specialization, thanks to our specialist Members, is truly extensive. We welcome suggestions of financing opportunities from MedPro Members and friends. We prefer companies with some demonstration of clinical efficacy which show promise of advancing the standard of care. They may be public or private.

MedGrow

Help us increase the size of our Membership

MedPro Investors LLC has grown to 156 healthcare professional Members. We hope and expect to continue increasing that number. Your connections and ability to help in this effort are extremely valuable. The larger we are, the more areas of expertise we can cover and the more we will be able to take advantage of opportunities. The best sources of new Members are current MedPro Members. For this reason, we encourage you to recommend other healthcare professionals to join our ranks. Please do not hesitate to send us the names of any healthcare professional friends, colleagues or associates that come to mind. A simple list including names and email addresses can be sent to steve@medproinvestors.com.



Visit Us:

<http://www.medproinvestors.com/>

Email Us:

isaac@medproinvestors.com

Call Us:

1-212-561-3611 (Steve)

Copyright © 2016 MedPro Investors LLC, All rights reserved.

[unsubscribe from this list](#) [update subscription preferences](#)
